Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May;59(5):2548-53.
doi: 10.1128/AAC.04632-14. Epub 2015 Feb 17.

Surveillance of artemisinin resistance in Plasmodium falciparum in India using the kelch13 molecular marker

Neelima Mishra  1 , Surendra Kumar Prajapati  1 , Kamlesh Kaitholia  1 , Ram Suresh Bharti  1 , Bina Srivastava  1 , Sobhan Phookan  1 , Anupkumar R Anvikar  1 , Vas Dev  1 , Gagan Singh Sonal  2 , Akshay Chandra Dhariwal  2 , Nicholas J White  3 , Neena Valecha  4
Affiliations

Surveillance of artemisinin resistance in Plasmodium falciparum in India using the kelch13 molecular marker

Neelima Mishra et al. Antimicrob Agents Chemother. 2015 May.

Abstract

Malaria treatment in Southeast Asia is threatened with the emergence of artemisinin-resistant Plasmodium falciparum. Genome association studies have strongly linked a locus on P. falciparum chromosome 13 to artemisinin resistance, and recently, mutations in the kelch13 propeller region (Pfk-13) were strongly linked to resistance. To date, this information has not been shown in Indian samples. Pfk-13 mutations were assessed in samples from efficacy studies of artemisinin combination treatments in India. Samples were PCR amplified and sequenced from codon 427 to 727. Out of 384 samples, nonsynonymous mutations in the propeller region were found in four patients from the northeastern states, but their presence did not correlate with ACT treatment failures. This is the first report of Pfk-13 point mutations from India. Further phenotyping and genotyping studies are required to assess the status of artemisinin resistance in this region.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Details of Plasmodium falciparum ACT efficacy study sites in India.
See this image and copyright information in PMC

References

    1. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. 2002. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2:209–218. doi:10.1016/S1473-3099(02)00239-6. - DOI - PubMed
    1. World Health Organization. 2001. Antimalarial drug combination therapy. World Health Organization, Geneva, Switzerland.
    1. Mohapatra PK, Prakash A, Taison K, Negmu K, Gohain AC, Namchoom NS, Wange D, Bhattacharyya DR, Goswami BK, Borgohain BK, Mahanta J. 2005. Evaluation of chloroquine (CQ) and sulphadoxine/pyrimethamine (SP) therapy in uncomplicated falciparum malaria in Indo-Myanmar border areas. Trop Med Int Health 10:478–483. doi:10.1111/j.1365-3156.2005.01401.x. - DOI - PubMed
    1. National Vector Borne Disease Control Programme. 2010. National drug policy on malaria. National Vector Borne Disease Control Programme, Directorate General of Health Services Ministry of Health and Family Welfare, Delhi, India.
    1. Dondorp AM, Nosten F, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Herdman T, An SS, Yeung S, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:455–467. doi:10.1056/NEJMoa0808859. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources